TY - JOUR
T1 - Additional cytogenetic features determines outcome in patients allografted for TP53 mutant acute myeloid leukemia
AU - Loke, Justin
AU - Labopin, Myriam
AU - Craddock, Charles
AU - Cornelissen, Jan J
AU - Labussière-Wallet, Hélène
AU - Wagner-Drouet, Eva Maria
AU - Van Gorkom, Gwendolyn
AU - Schaap, Nicolaas P M
AU - Kröger, Nicolaus M
AU - Veelken, Joan Hendrik
AU - Rovira, Montserrat
AU - Menard, Anne Lise
AU - Bug, Gesine
AU - Bazarbachi, Ali
AU - Giebel, Sebastian
AU - Brissot, Eolia
AU - Nagler, Arnon
AU - Esteve, Jordi
AU - Mohty, Mohamad
N1 - © 2022 American Cancer Society.
PY - 2022/8/1
Y1 - 2022/8/1
N2 - BACKGROUND: The presence of TP53 mutations is associated with an unfavorable outcome in patients allografted for acute myeloid leukemia (AML), leading some to question the benefit of an allogeneic stem cell transplantation (allo-SCT) for this patient group, although this has not been studied in a large cohort.METHODS: A total of 780 patients with AML in first complete remission, with either intermediate- or adverse-risk cytogenetics, whose TP53 mutation status was reported, were included in this study from the European Society for Blood and Marrow Transplantation.RESULTS: Two-year overall survival (OS) was impaired in patients (n = 179) with evidence of a TP53 mutation at diagnosis (35.1%; 95% confidence interval [CI], 26.7-43.7) as compared to the cohort without (n = 601) (64%; 95% CI, 59.1-68.4; P = .001). In patients with mutant TP53 AML with no evidence of either chromosome 17p loss (17p-) and/or complex karyotype (CK) (n = 53, 29.6%), 2-year OS was 65.2% (95% CI, 48.4-77.6). This was not significantly different to patients without TP53 mutations. In patients with mutant TP53 AML with either 17p- and/or CK (n = 126, 70.4%), the OS was lower (24.6%; 95% CI, 16.2-34; P = .001).CONCLUSIONS: In summary, the adverse prognostic effect of TP53 mutations in AML following an allo-SCT is not evident in patients with neither co-occurring 17p- and/or CK, and these data inform decisions regarding allo-SCT in patients with TP53 mutant AML.
AB - BACKGROUND: The presence of TP53 mutations is associated with an unfavorable outcome in patients allografted for acute myeloid leukemia (AML), leading some to question the benefit of an allogeneic stem cell transplantation (allo-SCT) for this patient group, although this has not been studied in a large cohort.METHODS: A total of 780 patients with AML in first complete remission, with either intermediate- or adverse-risk cytogenetics, whose TP53 mutation status was reported, were included in this study from the European Society for Blood and Marrow Transplantation.RESULTS: Two-year overall survival (OS) was impaired in patients (n = 179) with evidence of a TP53 mutation at diagnosis (35.1%; 95% confidence interval [CI], 26.7-43.7) as compared to the cohort without (n = 601) (64%; 95% CI, 59.1-68.4; P = .001). In patients with mutant TP53 AML with no evidence of either chromosome 17p loss (17p-) and/or complex karyotype (CK) (n = 53, 29.6%), 2-year OS was 65.2% (95% CI, 48.4-77.6). This was not significantly different to patients without TP53 mutations. In patients with mutant TP53 AML with either 17p- and/or CK (n = 126, 70.4%), the OS was lower (24.6%; 95% CI, 16.2-34; P = .001).CONCLUSIONS: In summary, the adverse prognostic effect of TP53 mutations in AML following an allo-SCT is not evident in patients with neither co-occurring 17p- and/or CK, and these data inform decisions regarding allo-SCT in patients with TP53 mutant AML.
KW - ALLOGENEIC TRANSPLANTATION
KW - FREQUENCY
KW - IMPACT
KW - INTENSITY
KW - MONOSOMAL KARYOTYPE
KW - MUTATIONS
KW - MYELODYSPLASTIC SYNDROME
KW - PROGNOSIS
KW - STEM-CELL TRANSPLANTATION
KW - TP53
KW - VERSUS-HOST-DISEASE
KW - acute myeloid
KW - allogeneic stem cell transplant
KW - cytogenetics
KW - leukemia
U2 - 10.1002/cncr.34268
DO - 10.1002/cncr.34268
M3 - Article
C2 - 35612815
SN - 0008-543X
VL - 128
SP - 2922
EP - 2931
JO - Cancer
JF - Cancer
IS - 15
ER -